Research News

• Media Release: Diabetes medication shows potential to reduce heart disease

  A new study from St. Michael's Hospital in collaboration with Western University sheds light on how a class of medications that help regulate blood sugar for patients with Type 2 diabetes can also protect against heart disease. The findings from the EMPA-HEART CardioLink-6 Trial, presented today at the ESC Congress 2019, organized by the European Society of Cardiology, and simultaneously published in Cell Metabolism, focus on the effect of a diabetes medication - empagliflozin - on cell repair in blood vessels and the resulting risks of heart disease. Empagliflozin is a medication that falls under a category of drugs called SGLT2 inhibitors, which lower blood sugar.



• Award: Dr. David Spence named to the Order of Canada
• Scientists look to defuse cardiac 'time bomb'
• Dentistry faculty internationally recognized for oral health research
• Gregory Dekaban, PhD, appointed Acting Chair, Microbiology & Immunology
• London scientists key players in national dementia strategy
• Four new CRCs announced
• Exploring the current landscape of arts and humanities in medical education